TY - JOUR
T1 - International Registry of Patients Carrying TGFBR1 or TGFBR2 Mutations
T2 - Results of the MAC (Montalcino Aortic Consortium)
AU - Jondeau, Guillaume
AU - Ropers, Jacques
AU - Regalado, Ellen
AU - Braverman, Alan
AU - Evangelista, Arturo
AU - Teixedo, Guisela
AU - De Backer, Julie
AU - Muiño-Mosquera, Laura
AU - Naudion, Sophie
AU - Zordan, Cecile
AU - Morisaki, Takayuki
AU - Morisaki, Hiroto
AU - Von Kodolitsch, Yskert
AU - Dupuis-Girod, Sophie
AU - Morris, Shaine A.
AU - Jeremy, Richmond
AU - Odent, Sylvie
AU - Adès, Leslie C.
AU - Bakshi, Madhura
AU - Holman, Katherine
AU - Lemaire, Scott
AU - Milleron, Olivier
AU - Langeois, Maud
AU - Spentchian, Myrtille
AU - Aubart, Melodie
AU - Boileau, Catherine
AU - Pyeritz, Reed
AU - Milewicz, Dianna M.
N1 - Funding Information:
Dr Jondeau received grant from Agence Nationale de la Recherche (ANR-14-CE15-00 12), Fédération Française de Cardiologie, Fondation Coeur et Recherche. Dr Boileau was supported by Programme Hospitalier de Recherche Clinique (AOM10108), Contrat de Recherche Clinique Assistance Publique Hopitaux de Paris (CRC15014), and Fondation Maladies Rares. Dr De Backer holds a grant as Senior Clinical Investigator from the Fund for Scientific Research (FWO), Flanders (Belgium). Dr Muiño-Mosquera is supported by a doctoral fellowship from the Special Research Fund (BOF) of the University of Ghent (Belgium). Drs Morisaki and H. Morisaki are beneficiary of a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan and grants from the Japan Science and Technology Corporation, Ministry of Health, Labour and Welfare of Japan, the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO), and Japan Agency for Medical Research and Development (AMED). Dr Morris is supported by National Heart, Lung, and Blood Institute of the National Institutes of Health award K23HL127266. Dr Milewicz is funded by National Institutes of Health (NIH) R01 HL62594, the John Ritter Foundation, Genetic Aortic Disorders Association (GADA), and the Temerty Family Foundation.
Publisher Copyright:
© 2016 American Heart Association, Inc.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Background-The natural history of aortic diseases in patients with TGFBR1 or TGFBR2 mutations reported by different investigators has varied greatly. In particular, the current recommendations for the timing of surgical repair of the aortic root aneurysms may be overly aggressive. Methods and Results-The Montalcino Aortic Consortium, which includes 15 centers worldwide that specialize in heritable thoracic aortic diseases, was used to gather data on 441 patients from 228 families, with 176 cases harboring a mutation in TGBR1 and 265 in TGFBR2. Patients harboring a TGFBR1 mutation have similar survival rates (80% survival at 60 years), aortic risk (23% aortic dissection and 18% preventive aortic surgery), and prevalence of extra-aortic features (29% hypertelorism, 53% cervical arterial tortuosity, and 27% wide scars) when compared with patients harboring a TGFBR2 mutation. However, TGFBR1 males had a greater aortic risk than females, whereas TGFBR2 males and females had a similar aortic risk. Additionally, aortic root diameter prior to or at the time of type A aortic dissection tended to be smaller in patients carrying a TGFBR2 mutation and was ≤45 mm in 6 women with TGFBR2 mutations, presenting with marked systemic features and low body surface area. Aortic dissection was observed in 1.6% of pregnancies. Conclusions-Patients with TGFBR1 or TGFBR2 mutations show the same prevalence of systemic features and the same global survival. Preventive aortic surgery at a diameter of 45 mm, lowered toward 40 in females with low body surface area, TGFBR2 mutation, and severe extra-aortic features may be considered.
AB - Background-The natural history of aortic diseases in patients with TGFBR1 or TGFBR2 mutations reported by different investigators has varied greatly. In particular, the current recommendations for the timing of surgical repair of the aortic root aneurysms may be overly aggressive. Methods and Results-The Montalcino Aortic Consortium, which includes 15 centers worldwide that specialize in heritable thoracic aortic diseases, was used to gather data on 441 patients from 228 families, with 176 cases harboring a mutation in TGBR1 and 265 in TGFBR2. Patients harboring a TGFBR1 mutation have similar survival rates (80% survival at 60 years), aortic risk (23% aortic dissection and 18% preventive aortic surgery), and prevalence of extra-aortic features (29% hypertelorism, 53% cervical arterial tortuosity, and 27% wide scars) when compared with patients harboring a TGFBR2 mutation. However, TGFBR1 males had a greater aortic risk than females, whereas TGFBR2 males and females had a similar aortic risk. Additionally, aortic root diameter prior to or at the time of type A aortic dissection tended to be smaller in patients carrying a TGFBR2 mutation and was ≤45 mm in 6 women with TGFBR2 mutations, presenting with marked systemic features and low body surface area. Aortic dissection was observed in 1.6% of pregnancies. Conclusions-Patients with TGFBR1 or TGFBR2 mutations show the same prevalence of systemic features and the same global survival. Preventive aortic surgery at a diameter of 45 mm, lowered toward 40 in females with low body surface area, TGFBR2 mutation, and severe extra-aortic features may be considered.
KW - Marfan syndrome
KW - acute aortic dissection gene
KW - aneurysm
KW - aortic disease
KW - aortic dissection
KW - aortic surgery
KW - diagnostics
KW - genetics
KW - human
KW - peripheral vascular disease
KW - sex differences
UR - http://www.scopus.com/inward/record.url?scp=85007271243&partnerID=8YFLogxK
U2 - 10.1161/CIRCGENETICS.116.001485
DO - 10.1161/CIRCGENETICS.116.001485
M3 - Article
C2 - 27879313
AN - SCOPUS:85007271243
SN - 1942-325X
VL - 9
SP - 548
EP - 558
JO - Circulation: Cardiovascular Genetics
JF - Circulation: Cardiovascular Genetics
IS - 6
ER -